利培酮治疗首发精神分裂症患者血中巢蛋白、微管相关蛋白的变化研究

Changes of nestin and MAP-2 in blood of patients with first-episode schizophrenia treated by risperidone

目的通过研究首发精神分裂症患者血浆中巢蛋白、微管相关蛋白变化,以探讨精神分裂症内在发病机制,为该疾病寻找更多诊疗手段。方法选择2018年3月至2019年3月本院收治的60例首发精神分裂症患者为病例组,同期于社区体检的健康自愿者中随机选取60例为对照组。病例组年龄(36.38±9.18)岁,男34例,女26例。对照组年龄(35.28±7.81)岁,男35例,女25例。两组均行巢蛋白、微管相关蛋白检测,其中病例组采用利培酮片剂治疗,于治疗前和治疗6周、6个月检测血浆巢蛋白、微管相关蛋白,并与对照组进行比较。病例组治疗前、治疗6周阳性与阴性症状量表(PANSS)测定,并进行治疗前后疗效比较。结果未经治疗的病例组巢蛋白和微管相关蛋白水平明显低于对照组,差异具有统计学意义(均P<0.01)。治疗6周后,血浆中巢蛋白、微管相关蛋白水平存在一定的升高,但与对照组比较,差异仍具有统计学意义(均P<0.01);治疗6个月后,血浆中巢蛋白、微管相关蛋白水平继续上升,与对照组比较,差异无统计学意义(均P>0.05)。病例组治疗后PANSS评分较治疗前明显下降,差异具有统计学意义(P<0.01)。经相关性分析提示,巢蛋白、微管相关蛋白水平与精神分裂症的症状程度呈负相关(均P<0.01)。结论巢蛋白、微管相关蛋白可作为精神分裂症早期干预及治疗疗效判断的一项重要生化指标。

Objective By studying the levels of nestin and MAP-2 in patients with schizophrenia,to explore the intrinsic pathogenesis of schizophrenia and to find more intervention and treatment methods for the disease.Methods 60 patients with first episode schizophrenia admitted to our hospital from March,2018 to March,2019 were selected as a case group,and 60 healthy volunteers who underwent community physical examination during the same period were randomly selected as a control group.There were 34 male and 26 female in the case group;and they were(36.38±9.18)years old.There were 35 male and 25 female in the control group;and they were(35.28±7.81)years old.The nestin and MAP-2 in both groups were detected.The control group were treated with risperidone tablets.Before and 6 weeks and 6 months after the treatment,the nestin and MAP-2 in the case group were detected,and compared with those of the control group.Positive and negative symptom scale(PANSS)was used to measure the patients before and 6 weeks after the treatment,and the efficacies before and after the treatment were compared.Results The levels of nestin and MAP-2 in the case group were significantly lower than those in the control group(both P<0.01).6 weeks after the treatment,the levels of nestin and MAP-2 increased in the case group,but with statistical differences from those in the control group(both P<0.01);6 months after the treatment,the levels significantly went up,with no statistical differences from those in the control group(both P>0.05).The PANSS score was significantly lower after than before the treatment in the case group(P<0.01).The correlation analysis suggested that nestin and MAP-2 levels were negatively correlated with the degree of schizophrenia symptoms(both P<0.01).Conclusion Nestin and MAP-2 can be used as important biochemical indicators in the evaluation of the efficacy of early intervention and treatment for schizophrenia.